Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell $-0.15 during today’s regular trading session, a -1.78% decrease from the previous closing price of $8.41. The company’s shares traded on stronger-than-usual volume today: $2.77M shares changed hands while the stock’s average volume is 2.71M shares per day. Amicus Therapeutics, Inc. (FOLD) has gained $1.00, or +13.77%, in the last 30 days. This year-to-date, the company’s shares have increased $3.29, or +66.20%. Over the last 12 months, FOLD’s stock price has risen $1.34, or +19.36%. The company’s 52-week range is $4.41 to $9.61.

Amicus Therapeutics, Inc. (FOLD) Earnings Surprises

Amicus Therapeutics, Inc. announced its recent quarter financial results after the market close on 09/05/2017, crushing consensus estimates with both its revenue and earnings. Amicus Therapeutics, Inc. posted net revenue of 4.17M, beating Wall Street analysts who had forecast $4.16M. The company reported EPS of $-0.39, below the consensus estimate calling for EPS of $-0.36 – a negative surprise of -8.94%.

Before that, quarter ending December 2016, Amicus Therapeutics, Inc. also surprised analysts by beating the consensus estimate. The Wall Street forecast had projected $-0.33 per share, and the company reported EPS of $-0.42 – also a -26.77% negative surprise. Revenue during the period amounted to $2.83M, while analysts were anticipating $3.75M.

In the quarter ending September 2016, Amicus Therapeutics, Inc. delivered an even larger earnings beat. Analysts, on average, were expecting $-0.31 per share, and the company reported EPS of $-0.33 – amounting to a negative surprise of -4.76%. Revenue during that quarter was posted at $2.13M , whereas the consensus estimate was predicting $1.71M.

The company is scheduled to announce its next quarterly financial results on 08/08/2017 after the market close. The average EPS estimate of 5 Wall Street analysts is $-0.37 per share, compared to the company’s reported EPS of $-0.4 per share in the year-ago quarter. Analysts are forecasting Amicus Therapeutics, Inc. to report revenue of about $6.87M, versus the $0 posted last year.

Amicus Therapeutics, Inc. (FOLD) Consensus Estimates and Price Target

The company’s consensus rating is currently Strong Buy, with 6 analysts rating it a Strong Buy, and 0 analysts rating it with a Hold. The average 12-month price target, as forecast by analysts, is $12.07 , 46.13% lower than the company’s closing price today